Quality of life and care experience in durable responders to immune checkpoint inhibitors for advanced or metastatic NSCLC or melanoma

Immuno-Oncology and Technology · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles